The European Commission Has Approved Boehringer Ingelheim/Eli Lilly Partnered Jardiance (Empagliflozin) For Adults With Chronic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved Jardiance (Empagliflozin), a drug developed in partnership by Boehringer Ingelheim and Eli Lilly, for use in adults with chronic kidney disease.
July 25, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's partnered drug Jardiance has received approval from the European Commission for use in adults with chronic kidney disease. This could potentially increase the company's revenue.
The approval of Jardiance by the European Commission is a positive development for Eli Lilly. This could potentially lead to increased sales and revenue for the company, as it expands the market for the drug. Therefore, this news is likely to have a positive impact on Eli Lilly's stock in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80